Literature DB >> 33898607

Scale up mHealth HIV interventions: site and public health perspectives and lessons learned from P3.

Mary E Paul1, Marné Castillo2, Patricia Emmanuel3, Jose A Bauermeister4, Leandro A Mena5, Patrick S Sullivan6, Lisa B Hightow-Weidman7.   

Abstract

A number of mobile health (mHealth) interventions have been shown to be effective and highly acceptable tools for improving human immunodeficiency virus (HIV) prevention and care for youth. Scale-up of efficacious technology-based interventions is challenging and best practices for scale-up have not been clearly established. Developers of mHealth interventions should have plans in mind for wide scale implementation throughout all stages of development including planning, during trials and during analysis and dissemination. We discuss an approach of focus on researchers, funders and potential implementers including members of the community, public health practitioners and policymakers during initial planning, trials, analysis and dissemination, and planning for scale-up. Development of the P3 (Prepared, Protected, emPowered) mobile application (app), an intervention built to encourage and increase pre-exposure prophylaxis (PrEP) adherence among young men who have sex with men (YMSM) and young transgender women who have sex with men (YTWSM), is discussed in terms of designing for scale-up and lessons learned. 2021 mHealth. All rights reserved.

Entities:  

Keywords:  Human immunodeficiency virus (HIV); app; implementation; mHealth; youth

Year:  2021        PMID: 33898607      PMCID: PMC8063006          DOI: 10.21037/mhealth-20-65

Source DB:  PubMed          Journal:  Mhealth        ISSN: 2306-9740


  1 in total

1.  Co-creation using crowdsourcing to promote PrEP adherence in China: study protocol for a stepped-wedge randomized controlled trial.

Authors:  Yongjie Sha; Chunyan Li; Yuan Xiong; Aniruddha Hazra; Jonathan Lio; Ivy Jiang; Haojie Huang; Jared Kerman; Jannelle Molina; Linghua Li; Ke Liang; Dandan Gong; Quanmin Li; Songjie Wu; Renslow Sherer; Joseph D Tucker; Weiming Tang
Journal:  BMC Public Health       Date:  2022-09-07       Impact factor: 4.135

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.